Furthermore, multiple prior GWAS studies reported that humans carrying a low-expression variant of FABP4 exhibit significant protection against the development of type 2 diabetes and cardiometabolic disease (Saksi et al, 2014; Zhao et al, 2017; Tuncman et al, 2006). This evidence concerns the gene FABP4 and type 2 diabetes mellitus.